Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WuXi PharmaTech, a biotechnology and medical device R&D outsourcing company, has signed an agreement with Johnson & Johnson Pharmaceutical R&D, a division of Janssen Pharmaceutica, to expand its pharmaceutical R&D services collaboration.
Subscribe to our email newsletter
The new broad agreement aims to deepen the already long-standing relationship between Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and WuXi PharmaTech.
WuXi, already a preferred research services provider to J&JPRD for discovery chemistry, will now provide integrated research services in the area of discovery chemistry, discovery biology, chemical and analytical development services, formulation, and preclinical and bio-analytical services, to enhance drug discovery and shorten development timelines.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “We are very pleased to expand our partnership with J&JPRD. This agreement leverages WuXi’s strong R&D capabilities from early stage discovery to commercial production to deliver reliable, high quality and cost-efficient services to J&JPRD. Our partnership demonstrates the strength of our innovation driven and fully integrated R&D service platform.”